Salivary lactoferrin levels in Down Syndrome: a case-control study
Loading...
Identifiers
Publication date
Advisors
Tutors
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Individuals with Down Syndrome (DS) have a high age-dependent risk of developing Alzheimer's disease (AD). In addition to genetic causes, this high risk involves dysregulated immune-inflammatory system. Low lactoferrin levels, one of the main antimicrobial proteins present in saliva, has been associated with AD. Here, we evaluated whether salivary lactoferrin levels change across the life span of individuals with DS. The study included 152 participants, 72 subjects with DS and 80 euploid individuals, and were divided into those under and over 45 years of age, accordingly with the age-dependent risk of AD. Median of salivary lactoferrin were higher among DS individual, in parallel to salivary total protein, but there were no differences in the ratio of lactoferrin to total protein in saliva between groups. Only DS individuals had higher median salivary lactoferrin levels in the age group under 45 years. Meanwhile non-significant differences were detected for the ratio salivary lactoferrin levels to total salivary protein between groups under 45 years, those levels were lower in DS subjects over 45 years old compared with the age-matched control group. Furthermore, the ratio of salivary lactoferrin levels to total protein in DS was associated with cognitive decline being lower in demented groups compared with mild and moderate cognitive impairment groups. In summary, this study indicates that salivary lactoferrin was dysregulated in DS, with significant lower ratio of salivary lactoferrin levels to total salivary proteins in individuals with DS over 45 years old, a population with a gradually increasing risk of AD.
Description
Keywords
Bibliographic citation
Antequera, D., Sande, L., Mato, E. G., Romualdi, D., Carrero, L., Municio, C., Diz, P., & Carro, E. (2025). Salivary lactoferrin levels in Down Syndrome: a case-control study. Brain, Behavior, and Immunity - Health, 46. https://doi.org/10.1016/J.BBIH.2025.100999
Relation
Has part
Has version
Is based on
Is part of
Is referenced by
Is version of
Requires
Publisher version
https://doi.org/10.1016/j.bbih.2025.100999Sponsors
This work was funded by Grants from Instituto de Salud Carlos III ( PI22CIII/00042 ), CIBERNED ( CB05/06/0022 , PI2021/03 ), and the Spanish Ministry of Science and Innovation ( PID2022-139195OB-I00 ).
Rights
© 2025 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
Attribution-NonCommercial-NoDerivatives 4.0 International
Attribution-NonCommercial-NoDerivatives 4.0 International







